Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design.

Laukens D, Brinkman BM, Raes J, De Vos M, Vandenabeele P.

FEMS Microbiol Rev. 2016 Jan;40(1):117-32. doi: 10.1093/femsre/fuv036. Epub 2015 Aug 30. Review.

2.

Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death.

Laukens D, Devisscher L, Van den Bossche L, Hindryckx P, Vandenbroucke RE, Vandewynckel YP, Cuvelier C, Brinkman BM, Libert C, Vandenabeele P, De Vos M.

Lab Invest. 2014 Dec;94(12):1419-30. doi: 10.1038/labinvest.2014.117. Epub 2014 Oct 13.

3.

The skin microbiome of caspase-14-deficient mice shows mild dysbiosis.

Kubica M, Hildebrand F, Brinkman BM, Goossens D, Del Favero J, Vercammen K, Cornelis P, Schröder JM, Vandenabeele P, Raes J, Declercq W.

Exp Dermatol. 2014 Aug;23(8):561-7. doi: 10.1111/exd.12458. Epub 2014 Jul 16.

PMID:
24863253
4.

Gut microbiota affects sensitivity to acute DSS-induced colitis independently of host genotype.

Brinkman BM, Becker A, Ayiseh RB, Hildebrand F, Raes J, Huys G, Vandenabeele P.

Inflamm Bowel Dis. 2013 Nov;19(12):2560-7. doi: 10.1097/MIB.0b013e3182a8759a.

PMID:
24105395
5.

Caspase deficiency alters the murine gut microbiome.

Brinkman BM, Hildebrand F, Kubica M, Goosens D, Del Favero J, Declercq W, Raes J, Vandenabeele P.

Cell Death Dis. 2011 Oct 20;2:e220. doi: 10.1038/cddis.2011.101.

6.

Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways.

Kaczmarek A, Brinkman BM, Heyndrickx L, Vandenabeele P, Krysko DV.

J Pathol. 2012 Mar;226(4):598-608. doi: 10.1002/path.3009. Epub 2011 Dec 5.

PMID:
21960132
7.

RNAprotect saliva: An optimal room- temperature stabilization reagent for the salivary transcriptome.

Park NJ, Yu T, Nabili V, Brinkman BM, Henry S, Wang J, Wong DT.

Clin Chem. 2006 Dec;52(12):2303-4. No abstract available.

8.

Characterization of salivary RNA by cDNA library analysis.

Park NJ, Zhou X, Yu T, Brinkman BM, Zimmermann BG, Palanisamy V, Wong DT.

Arch Oral Biol. 2007 Jan;52(1):30-5. Epub 2006 Oct 18.

9.

Characterization of RNA in saliva.

Park NJ, Li Y, Yu T, Brinkman BM, Wong DT.

Clin Chem. 2006 Jun;52(6):988-94. Epub 2006 Apr 6.

10.

Disease mechanism and biomarkers of oral squamous cell carcinoma.

Brinkman BM, Wong DT.

Curr Opin Oncol. 2006 May;18(3):228-33. Review.

PMID:
16552233
11.

Splice variants as cancer biomarkers.

Brinkman BM.

Clin Biochem. 2004 Jul;37(7):584-94. Review.

PMID:
15234240
12.

A stimulus-specific role for CREB-binding protein (CBP) in T cell receptor-activated tumor necrosis factor alpha gene expression.

Falvo JV, Brinkman BM, Tsytsykova AV, Tsai EY, Yao TP, Kung AL, Goldfeld AE.

Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3925-9.

13.

Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter.

Falvo JV, Uglialoro AM, Brinkman BM, Merika M, Parekh BS, Tsai EY, King HC, Morielli AD, Peralta EG, Maniatis T, Thanos D, Goldfeld AE.

Mol Cell Biol. 2000 Mar;20(6):2239-47.

14.

Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression.

Brinkman BM, Telliez JB, Schievella AR, Lin LL, Goldfeld AE.

J Biol Chem. 1999 Oct 22;274(43):30882-6.

15.

Signaling through the lymphotoxin-beta receptor stimulates HIV-1 replication alone and in cooperation with soluble or membrane-bound TNF-alpha.

Marshall WL, Brinkman BM, Ambrose CM, Pesavento PA, Uglialoro AM, Teng E, Finberg RW, Browning JL, Goldfeld AE.

J Immunol. 1999 May 15;162(10):6016-23.

16.

Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis.

Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM, Breedveld FC, Verweij CL.

Hum Immunol. 1999 Feb;60(2):140-4.

PMID:
10027781
17.

Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis.

Kaijzel EL, van Krugten MV, Brinkman BM, Huizinga TW, van der Straaten T, Hazes JM, Ziegler-Heitbrock HW, Nedospasov SA, Breedveld FC, Verweij CL.

Mol Med. 1998 Nov;4(11):724-33.

18.

Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?

Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, Breedveld FC, Verweij CL.

Br J Rheumatol. 1997 May;36(5):516-21.

PMID:
9189051
19.

Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance.

Mordmüller BG, Metzger WG, Juillard P, Brinkman BM, Verweij CL, Grau GE, Kremsner PG.

Eur Cytokine Netw. 1997 Mar;8(1):29-35.

PMID:
9110145
20.

TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.

Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-Gonzalez A, van Oosten BW, Polman CH, Peña AS.

J Neuroimmunol. 1997 Feb;72(2):149-53.

PMID:
9042107
21.

Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons.

Brinkman BM, Keet IP, Miedema F, Verweij CL, Klein MR.

J Infect Dis. 1997 Jan;175(1):188-90.

PMID:
8985218
22.

Allele-specific quantification of TNFA transcripts in rheumatoid arthritis.

Brinkman BM, Huizinga TW, Breedveld FC, Verweij CL.

Hum Genet. 1996 Jun;97(6):813-8.

PMID:
8641702
23.

The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes.

Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, Dijkmans BA, Verweij C.

Antimicrob Agents Chemother. 1996 Apr;40(4):934-40.

24.

Regulation of tumor necrosis factor-alpha production: basic aspects and pharmacological modulation.

Huizinga TW, Brinkman BM, Verweij CL.

J Rheumatol. 1996 Mar;23(3):416-8. No abstract available.

PMID:
8832975
25.

Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene.

Brinkman BM, Kaijzel EL, Huizinga TW, Giphart MJ, Breedveld FC, Verweij CL.

Hum Genet. 1995 Oct;96(4):493.

PMID:
7557979
26.

Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation.

Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL.

J Inflamm. 1995-1996;46(1):32-41.

PMID:
8832970
27.

Tumor necrosis factor alpha-308 gene variants in relation to major histocompatibility complex alleles and Felty's syndrome.

Brinkman BM, Giphart MJ, Verhoef A, Kaijzel EL, Naipal AM, Daha MR, Breedveld FC, Verweij CL.

Hum Immunol. 1994 Dec;41(4):259-66.

PMID:
7883593
28.

Expression of granzymes A and B in synovial tissue from patients with rheumatoid arthritis and osteoarthritis.

Kummer JA, Tak PP, Brinkman BM, van Tilborg AA, Kamp AM, Verweij CL, Daha MR, Meinders AE, Hack CE, Breedveld FC.

Clin Immunol Immunopathol. 1994 Oct;73(1):88-95.

PMID:
7923921
29.

Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis.

Verjans GM, Brinkman BM, Van Doornik CE, Kijlstra A, Verweij CL.

Clin Exp Immunol. 1994 Jul;97(1):45-7.

30.

Detection of intracellular interferon-gamma by light microscopy using an immunoperoxidase technique: correlation with the corresponding mRNA and protein product.

Dolhain RJ, Andersson U, ter Haar NT, Brinkman BM, Verweij CL, Daha MR, Breedveld FC, Miltenburg AM.

J Leukoc Biol. 1993 Dec;54(6):545-51.

PMID:
7504045

Supplemental Content

Loading ...
Support Center